Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits' eyes

Doc Ophthalmol. 2019 Feb;138(1):3-19. doi: 10.1007/s10633-018-9664-8. Epub 2018 Nov 19.

Abstract

Purpose: To assess the in vivo release profile and the retinal toxicity of a poly (lactic-co-glycolic acid) (PLGA) sustained-release sirolimus (SRL) intravitreal implant in normal rabbit eyes.

Methods: PLGA intravitreal implants containing or not SRL were prepared, and the viability of ARPE-19 and hES-RPE human retinal cell lines was examined after 24 and 72 h of exposure to implants. New Zealand rabbits were randomly divided into two groups that received intravitreal implants containing or not SRL. At each time point (1-8 weeks), four animals from the SRL group were euthanized, the vitreous was collected, and drug concentration was calculated. Clinical evaluation of the eyes was performed weekly for 8 weeks after administration. Electroretinography (ERG) was recorded in other eight animals, four for each group, at baseline and at 24 h, 1, 4, 6, and 8 weeks after the injection. ERG was carried out using scotopic and photopic protocols. The safety of the implants was assessed using statistical analysis of the ERG parameters (a and b waves, a and b implicit time, B/A ratio, oscillatory potential, and Naka-Rushton analysis) comparing the functional integrity of the retina between the PLGA and SRL-PLGA groups. After the last electrophysiological assessment, the rabbits were euthanized and retinal histopathology was realized.

Results: After 24 and 72 h of incubation with PLGA or SRL-PLGA implants, ARPE-19 and hES-RPE cells showed viability over 70%. The maximum concentration of SRL (199.8 ng/mL) released from the device occurred within 4 weeks. No toxic effects of the implants or increase in the intraocular pressure was observed through clinical evaluation of the eye. ERG responses showed no significant difference between the eyes that received PLGA or SRL-PLGA implants at baseline and throughout the 8 weeks of follow-up. No remarkable difference in retinal histopathology was detected in rabbit eyes treated with PLGA or SRL-PLGA implants.

Conclusions: Intravitreal PLGA or SRL-PLGA implants caused no significant reduction in cell viability and showed no evident toxic effect on the function or structure of the retina of the animals. SRL was released from PLGA implant after application in the vitreous of rabbits during 8 weeks.

Keywords: Biodegradable implant; Cell viability; Electroretinography; Intravitreal drug delivery; Sirolimus; Toxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absorbable Implants
  • Animals
  • Biological Availability
  • Cell Line
  • Cell Survival
  • Drug Delivery Systems
  • Drug Implants
  • Electroretinography
  • Embryonic Stem Cells / drug effects
  • Humans
  • Immunosuppressive Agents / pharmacokinetics*
  • Immunosuppressive Agents / toxicity*
  • Intravitreal Injections
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Rabbits
  • Retina / drug effects
  • Retinal Pigment Epithelium / drug effects*
  • Sirolimus / pharmacokinetics*
  • Sirolimus / toxicity*
  • Vitreous Body / metabolism*

Substances

  • Drug Implants
  • Immunosuppressive Agents
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Sirolimus